{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-034635","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2022-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.954372+00:00","generated_at":"2026-06-24T23:41:32.495899+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Hoth Therapeutics shareholders reject reverse stock split; Nasdaq compliance at risk","bullets":["Shareholders re-elected directors Robb Knie, David Sarnoff, Graig Springer, Wayne Linsley.","Ratified Withum as independent auditor for FY2022; approved 2022 Omnibus Equity Incentive Plan.","Reverse stock split proposal (1:2 to 1:20) failed, with 13,162,362 for, 3,116,563 against.","Nasdaq minimum bid price compliance deadline is June 28, 2022; company considers special meeting to revisit reverse split.","Failure to regain compliance could result in delisting from Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-034635","json":"https://secwatch.observer/filing/0001213900-22-034635.json","markdown":"https://secwatch.observer/filing/0001213900-22-034635.md","text":"https://secwatch.observer/filing/0001213900-22-034635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390022034635/0001213900-22-034635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390022034635/ea161987-8k_hoththera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:41:32.495899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}